Jump to main content
Jump to site search

Issue 29, 2015
Previous Article Next Article

Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors

Author affiliations

Abstract

Currently available drugs to treat malaria are often ineffective due to the acquisition of drug resistance. In this context, drugs with innovative modes of action and no liability to cross-resistance are urgently needed. Recently, subtilisin-like protease 1, a P. falciparum serine protease involved in merozoite egress from red blood cells and invasion, has been identified as potential drug target. We describe herein the development of a series of potent PfSUB1 inhibitors. Combining a straightforward synthetic approach, an in depth structure–activity study and in silico investigation, we identified the most potent inhibitors known to date, characterized by an improved enzyme inhibitory potency and a reduced peptidic character over the prototypic peptides.

Graphical abstract: Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors

Back to tab navigation

Supplementary files

Publication details

The article was received on 22 Jan 2015, accepted on 19 Feb 2015 and first published on 19 Feb 2015


Article type: Paper
DOI: 10.1039/C5RA01170A
Author version available: Download Author version (PDF)
Citation: RSC Adv., 2015,5, 22431-22448
  •   Request permissions

    Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors

    S. Giovani, M. Penzo, S. Butini, M. Brindisi, S. Gemma, E. Novellino, G. Campiani, M. J. Blackman and S. Brogi, RSC Adv., 2015, 5, 22431
    DOI: 10.1039/C5RA01170A

Search articles by author

Spotlight

Advertisements